Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8326 to 8340 of 8941 results

  1. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    Discontinued Reference number: GID-TA10906

    Technology appraisal guidance
    Discontinued

  2. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    Discontinued Reference number: GID-TA11357

    Technology appraisal guidance
    Discontinued

  3. Pralsetinib for thyroid cancer [ID4018]

    Discontinued Reference number: GID-TA10910

    Technology appraisal guidance
    Discontinued

  4. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    Discontinued Reference number: GID-HST10032

    Highly specialised technologies guidance
    Discontinued

  5. LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

    Discontinued Reference number: GID-TA10728

    Technology appraisal guidance
    Discontinued

  6. Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629

    Discontinued Reference number: GID-TA10841

    Technology appraisal guidance
    Discontinued

  7. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development Reference number: GID-TA10899 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development Reference number: GID-TA11443 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development Reference number: GID-TA11482 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued Reference number: GID-TA11522

    Technology appraisal guidance
    Discontinued

  12. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued Reference number: GID-TA11041

    Technology appraisal guidance
    Discontinued

  13. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    Discontinued Reference number: GID-TA11026

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    Discontinued Reference number: GID-TA11024

    Technology appraisal guidance
    Discontinued

  15. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued Reference number: GID-TA10316

    Technology appraisal guidance
    Discontinued